{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106540","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.761055+00:00","generated_at":"2026-05-17T15:48:45.510937+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Septerna Q2 net loss $24.8M; cash $379.2M; Novo Nordisk upfront $195M extends runway into 2029","bullets":["Net loss of $24.8M for Q2 2025, up from $16.4M in Q2 2024; R&D expenses $22.2M, G&A $6.9M.","Cash, cash equivalents and marketable securities $379.2M at June 30, 2025; plus $195M upfront from Novo Nordisk received in July, extending cash runway at least into 2029.","PTH1R agonist program: development candidate selection expected in Q3 2025, Phase 1 start in H1 2026.","SEP-631 Phase 1 trial initiating in Q3 2025 for mast cell diseases.","COO Liz Bhatt promoted to President effective August 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106540","json":"https://secwatch.observer/filing/0000950170-25-106540.json","markdown":"https://secwatch.observer/filing/0000950170-25-106540.md","text":"https://secwatch.observer/filing/0000950170-25-106540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000095017025106540/0000950170-25-106540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000095017025106540/sepn-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:48:45.510937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}